RobotDreams · Medical Intelligence Company

Decoding the Blood Code

Where routine blood test becomes precision medicine for clinical decision support, pharma biomarker intelligence, and CBC data asset.

THOLAN LAB diagram showing a haemoanalyzer feeding routine CBC data into the THOLAN LAB signal extraction layer, with clinical, pharma, and data intelligence outputs.
0new hardware
0extra blood draws
3strategic domains
1intelligence layer
thesis

Not another diagnostics test. A new interpretation layer.

RobotDreams is built on a simple insight: routine haematology data contains more signal than conventional CBC reporting exposes. THOLAN LAB adds intelligence to a workflow hospitals already use every day.

clinical bottleneck

The first blood draw is underused.

In emergency care, patients can wait hours for serial testing. In pharma, high-value blood signals are often invisible to conventional readouts. In population health, routine CBC data is treated as disposable instead of strategic.

platform

One intelligence layer. Three outputs.

Input

Routine haematology data

THOLAN LAB uses data already generated by existing analysers and clinical workflows.

Core

Signal extraction

Raw cellular patterns are transformed into biomarker vectors and calibrated, auditable outputs.

Output

Clinical, pharma and data intelligence

The same core powers decision support, haematological cytomics/CDx, and long-term CBC data intelligence.

business architecture

Three domains. One company.

Each domain has a different time horizon, but they reinforce the same platform. Clinical use builds workflow credibility. Pharma expands the signal library. Data creates defensibility.

Domain I

Clinical decision support

First-draw intelligence for acute workflows, beginning with suspected Acute Coronary Syndrome.

ACSED flowSaMD
Domain II

Haematological cytomics & CDx

Biomarker discovery, patient stratification and companion-diagnostic co-development for pharma partners.

biomarkersPD readoutCDx
Domain III

CBC data intelligence

A structured, privacy-conscious haematology data asset linking cellular patterns to outcomes and response.

RWEfederated datamoat
compounding value

The data moat compounds quietly.

Every clinical deployment and pharma partnership can expand the reference base. The platform becomes more valuable as it is used.

Clinical deployment

Creates workflow credibility, evidence, and revenue from acute-care use cases.

Pharma cytomics

Adds disease-specific and treatment-specific haematological signatures.

CBC intelligence

Builds a proprietary data asset that becomes harder to replicate over time.

investor thesis

A platform company with multiple value horizons.

RobotDreams is not a single-use diagnostic story. The company is designed around layered value creation: clinical revenue, pharma partnerships and long-term CBC data intelligence.

near termACS decision support establishes clinical credibility and per-test software revenue.
mid termHaematological cytomics opens partner-funded biomarker and CDx opportunities.
long termCBC data intelligence creates a defensible strategic asset.
team

Built by operators, scientists, and clinical advisors.

Leadership team Core team Advisors

The team is structured around company leadership, specialist execution, and external clinical and legal guidance — matching the three horizons of THOLAN LAB: product, evidence, and scale.

Leadership team

Executive ownership across company building, operations, technology, product, and strategic scaling.

Portrait of Ulrich Weigelt
Co-Founder & CEO

Ulrich Weigelt

Company builder responsible for management and global growth, with 30+ years of leadership experience across eLearning, performance support software, and startup scaling.

growthmanagement
Portrait of Alexander Schwarzfurtner
COO

Alexander Schwarzfurtner

Operations leader with 20 years in semiconductors, founder experience, and a track record of building production and organizational structures through company scale-up.

operationsscale-up
Portrait of Dimitrij Shulkin
Co-Founder & CTO

Dimitrij Shulkin, MSc

AI and computational engineering leader with 10+ years building AI-based solutions for aerospace, automotive, and IT, including work with global industrial partners.

AIengineering
Portrait of Marvie Demit
CPO

Marvie Demit

Product leader with 12 years across life sciences, medical, IVD, bioinformatics, data science, and product operations for AI-driven health technology.

productIVD
Rest of the team

Scientific, mathematical, regulatory, data science, medical, and software capabilities for turning routine CBC data into a defensible platform.

Portrait of Prof. Dr. Aleksandr Pushkin
Founding scientist & co-inventor

Prof. Dr. Aleksandr Pushkin, MD

Founding father of the underlying method, co-inventor, and clinical laboratory diagnostics expert with leadership experience in hospital laboratory medicine.

clinical labmethod
Portrait of Dr. Joseph Doolittle
Mathematician

Dr. Joseph Doolittle

Mathematician focused on high-dimensional problems, combinatorics, geometry, topology, and the structures that emerge in complex data analysis.

mathhigh-dimensional
Portrait of Michal Pallo
Head of QARA

Michal Pallo

Quality and regulatory affairs professional with EU MDR, IVDR, ISO 13485, technical documentation, clinical evidence, risk management, and QMS experience.

QARAIVDR
Portrait of Maryam Haghdoust
Junior Data Scientist

Maryam Haghdoust

Data scientist with a computer engineering background, AI and cybersecurity studies, and hands-on experience with neural networks, fraud detection, forecasting, and NLP.

data scienceML
Portrait of Philipp Robin
Working student

Philipp Robin

Human medicine student at the Medical University of Graz in cooperation with JKU Linz, bringing medical context and earlier international business training.

medicinebusiness
Portrait of Martin Jauregui Ortun
Software developer

Martin Jauregui Ortun

Full-stack developer with a biology and medical diagnostics background, focused on data-driven web applications, backend systems, and modern UI development.

softwarefull-stack
Advisors

Strategic, clinical cardiology, cardiovascular science, and legal/corporate guidance to strengthen evidence generation, governance, and commercialization.

Portrait of Steffen Hellmold
Strategic advisor

Steffen Hellmold

Technology and business development executive with 30+ years in semiconductors and storage, including senior roles at Twist Bioscience, Western Digital, Seagate, Micron, Samsung, and others.

strategydeep tech
Portrait of Prof. Andreas Zirlik
Clinical cardiology advisor

Prof. Andreas Zirlik, MD

Professor of Internal Medicine and Cardiology at the Medical University of Graz and Head of Clinical Division of Cardiology at the University Heart Center Graz.

cardiologyclinical
Portrait of Dr. Christian Pfandl
Legal & corporate advisor

Dr. Christian Pfandl

Corporate lawyer with more than two decades of experience across corporate law, company law, M&A, supervisory board work, and trusteeship.

legalM&A
Portrait of Assoz. Prof. Heiko Bugger
Cardiovascular science advisor

Assoz. Prof. Heiko Bugger, MD

Senior physician and Professor of Cardiovascular Immunology at the Medical University of Graz with scientific training across Yale, Utah, and Freiburg.

immunologycardiology
partners & funders

An ecosystem around evidence, funding, and market access.

RobotDreams sits inside a European health-tech network spanning public innovation funding, clinical research, commercialization support, export expertise, and specialist life-science ecosystems.

Funding

Public innovation support.

Funding and public-support infrastructure helps de-risk the path from R&D into regulated health-tech execution.

Clinical & research

Evidence generation network.

Academic and clinical partners support the scientific grounding needed for defensible medical AI and biomarker development.

Commercial ecosystem

Market access pathways.

Internationalization, incubation, and commercialization partners help connect the platform to pharma, clinical, and strategic buyers.

Public funding
FFG

Austrian Research Promotion Agency funding and innovation support for high-risk R&D.

Funding partner
Public funding
Austria Wirtschaftsservice

Austria's federal promotional bank and public funding ecosystem for company growth.

Funding partner
International visibility
Expo 2025 Austria

International visibility through the Austria / Expo 2025 Osaka, Kansai, Japan ecosystem.

Showcase ecosystem
Clinical & research
Medical University of Graz

Clinical research and academic ecosystem around laboratory medicine, cardiology, and translational evidence.

Scientific partner
Commercial ecosystem
Plug and Play

Startup and corporate innovation ecosystem supporting commercialization and strategic market access.

Commercialization
Export & market access
ICS Internationalisierungscenter Steiermark

Internationalization and export support from the Styrian business ecosystem.

Market access
Space & deep tech
ESA Commercialisation Gateway

European Space Agency commercialization ecosystem connecting deep-tech capabilities with market opportunities.

Deep-tech ecosystem
Life science cluster
Human Technology Styria

Specialist life-science cluster connecting health-tech, med-tech, pharma, and research capabilities in Styria.

Life-science network
Incubation
Science Park Graz / ESA BIC Austria

Startup incubation, acceleration, and ESA BIC Austria support from the Graz innovation ecosystem.

Incubation
Investor & partnership contact

Start the conversation.

Use the form to start a conversation with RobotDreams. Share your contact details and partnership interest, and our team will follow up directly. By submitting the form, you acknowledge the NDA terms and consent to being contacted regarding your request.

Read Mutual Non-Disclosure Agreement
MUTUAL NON-DISCLOSURE AGREEMENT This Agreement is entered into as of the date on which it is accepted (the “Effective Date”), by and between the company or individual that makes the documents available, as identified upon online registration, hereinafter known as "Party A", and the individual or entity that accesses or downloads the documents made available by Party A, hereinafter known as "Party B". WHEREAS Party A and Party B, hereinafter known as the “Parties”, have an interest in participating in discussions wherein either Party may share information with the other that the disclosing Party considers being proprietary and confidential to itself (“Confidential Information”); and WHEREAS the Parties agree that Confidential Information of a Party may include, but not be limited to, that Party’s: (1) business plans, methods, and practices; (2) personnel, customers, and suppliers; (3) inventions, processes, methods, products, patent applications, and other proprietary rights; (4) specifications, drawings, sketches, models, samples, tools, computer programs, technical information, or other related information; NOW, THEREFORE, the Parties agree as follows: 1. Either Party may disclose Confidential Information to the other Party in confidence provided that the disclosing Party identifies such information as proprietary and confidential either by marking it, in the case of written materials, or, in the case of information that is disclosed orally or written materials that are not marked, by notifying the other Party of the proprietary and confidential nature of the information, such notification to be done orally, by email or written correspondence, or via other means of communication as might be appropriate. 2. When informed of the proprietary and confidential nature of Confidential Information that has been disclosed by the other Party, the receiving Party (“Recipient”) shall, for a period of five years from the date of disclosure, refrain from disclosing such Confidential Information to any contractor or other third party without prior, written approval from the disclosing Party and shall protect such Confidential Information from inadvertent disclosure to a third party using the same care and diligence that the Recipient uses to protect its own proprietary and confidential information, but in no case less than reasonable care. The Recipient shall ensure that each of its employees, officers, directors, or agents who has access to Confidential Information disclosed under this Agreement is informed of its proprietary and confidential nature and is required to abide by the terms of this Agreement. The Recipient of Confidential Information disclosed under this Agreement shall promptly notify the disclosing Party of any disclosure of such Confidential Information in violation of this Agreement or of any subpoena or other legal process requiring production or disclosure of said Confidential Information. For the avoidance of doubt, this Agreement governs only the non-disclosure of Confidential Information and does not restrict either Party’s use of its own knowledge, skills, ideas, concepts, or insights for its own business purposes, provided that such use does not involve the disclosure of the other Party’s Confidential Information to any third party in violation of this Agreement. 3. All Confidential Information disclosed under this Agreement shall be and remain the property of the disclosing Party and nothing contained in this Agreement shall be construed as granting or conferring any rights to such Confidential Information on the other Party. The Recipient shall honor any request from the disclosing Party to promptly return or destroy all copies of Confidential Information disclosed under this Agreement and all notes related to such Confidential Information. The Parties agree that the disclosing Party will suffer irreparable injury if its Confidential Information is made public, released to a third party or otherwise disclosed in breach of this Agreement and that the disclosing Party shall be entitled to obtain injunctive relief against a threatened breach or continuation of such breach and, in the event of such breach, an award of actual damages from an Austrian court of competent jurisdiction. Notwithstanding the foregoing, in no event shall either Party be liable to the other for any indirect, incidental, consequential, special, or punitive damages, or for any loss of profits, revenue, or business opportunities, arising out of or in connection with this Agreement, regardless of the form of action. The aggregate liability of either Party arising out of or in connection with this Agreement shall in no event exceed EUR [Amount]. 4. The terms of this Agreement shall not be construed to limit either Party’s right to develop independently or acquire products without use of the other Party’s Confidential Information. The disclosing party acknowledges that the Recipient may currently or in the future be developing information internally, or receiving information from other parties, that is similar to the Confidential Information. Nothing in this Agreement will prohibit the Recipient from developing or having developed for it products, concepts, systems, or techniques that are similar to or compete with the products, concepts, systems, or techniques contemplated by or embodied in the Confidential Information, provided that the Recipient does not violate any of its obligations under this Agreement in connection with such development. 5. Notwithstanding the above, the Parties agree that information shall not be deemed Confidential Information and the Recipient shall have no obligation to hold in confidence such information, where such information: (a) Is already known to the Recipient, having been disclosed to the Recipient by a third party without such third party having an obligation of confidentiality to the disclosing Party; (b) Is or becomes publicly known through no wrongful act of the Recipient, its employees, officers, directors, or agents; (c) Is independently developed by the Recipient without reference to any Confidential Information disclosed hereunder; (d) Is approved for release (and only to the extent so approved) by the disclosing Party; or (e) Is disclosed pursuant to the lawful requirement of a court or governmental agency or where required by operation of law. 6. Nothing in this Agreement shall be construed to constitute an agency, partnership, joint venture or other similar relationship between the Parties. 7. Neither Party will, without prior approval of the other Party, make any public announcement of or otherwise disclose the existence or the terms of this Agreement. 8. This Agreement contains the entire agreement between the Parties and in no way creates an obligation for either Party to disclose information to the other Party or to enter into any other agreement. 9. This Agreement shall remain in effect for a period of five years from the Effective Date unless otherwise terminated by either Party giving notice to the other of its desire to terminate this Agreement. The requirement to protect Confidential Information disclosed under this Agreement shall survive termination of this Agreement. 10. This contract shall be governed by the laws of the Federal Republic of Austria, with the exception of the provisions of the UN Convention on Contracts for the International Sale of Goods (CISG), insofar as these refer to foreign law. The exclusive place of jurisdiction for all disputes between the parties arising from or in connection with this contract shall be Graz. The statutory provisions on exclusive places of jurisdiction shall remain unaffected. By clicking “Accept,” Party B confirms that it has read and understood this Agreement and agrees to be legally bound by its terms. Such electronic acceptance is given on the Effective Date and has the same legal effect as a handwritten signature.
Next step

Invest in the blood-data intelligence layer.

RobotDreams is building the future of precision medicine in haematology from data the healthcare system already generates.